Randomized, triple-blind, phase III trial Completely resected, pathologically confirmed stage IB (tumours of ≥4 cm in diameter), II, or IIIA Pembrolizumab (n=590) vs PBO (n=587)

15 Mar

Pancreatic Cancer

New Indication: Sotorasib in kRAS G12C Mutant Pancreatic Cancer

International, multicenter, open-label, phase 1–2 trial Pretreated, locally advanced or metastatic pancreatic cancer with KRAS p.G12C mutation Sotorasib (n=38)

15 Mar

Head and Neck Cancer

New Indicaiton: DOCEtaxel as a Radiosensitizer in Head and Neck Cancer

Phase II/III, randomized, open-label study Cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC) Docetaxel-RT (n=180) vs. RT (n=176)

10 Jan

Chronic Lymphocytic Leukemia

New Reference: Zanubrutinib for R/R CLL

Phase III, randomized, open-label study (ALPINE) Relapsed or refractory CLL/SLL Zanubritinib (n=327) vs. İbrutinib (n=325)

15 Mar

Colorectal Cancer

New Drug: Adagrasib with/without Cetuximab in kRAS G12C Mutant Colorectal Cancer

Phase I-II, nonrandomized, open-label trial Pretreated metastatic colorectal cancer patients with KRAS G12C mutation Adagrasib + Cetuximab (n=32) and Adagrasib (n=44)

10 Jan

Melanoma

New Protocol: Atezolizumab with Vemurafenib and Cobimetinib in Metastatic Melanoma

Phase III, multicenter, randomized, double-blind trial Previously untreated unresectable stage IIIc or stage IV melanoma Atezolizumab (n=256) vs. PBO + vemurafenib + cobiventinib (

10 Jan

Ovarian Cancer

New Drug: Mirvetuximab Soravtansine in FRalpha Positive Ovarian Cancer

Single-arm, Phase-3 trial (SONAYA) Platinum-resistant epithelial ovarian cancer (up to three prior lines of systemic therapy; all patients were required to have received bevacizuma

10 Jan

Acute myeloid leukemia

New Drug: Enasidenib in IDH2 Mutant AML

Phase III, randomized, open-label study Patients aged ≥60 years with late-stage, mutant-IDH2 acute myeloid leukemia (AML) relapsed/refractory (R/R) to 2 or 3 prior AML-directed t

10 Jan

Non-Small Cell Lung Cancer

New Indication: Durvalumab with Tremelimumab in Metastatic NSCLC

Phase III, randomized, three-arm, open-label study (POSEIDON) Previously untreated mNSCLC Arm A: (T+C+CT) Tremelimumab 75 mg plus durvalumab 1,500 mg and chemotherapy for up to fou

Easiest Access to Our Chemotherapy Protocol Library

Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries